Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Jean‐Michel Molina, Steven L. Chuck, Bonaventura Clotet et al.|The Lancet Infectious Diseases|2011

Cited by 172